Eisai US Subsidiary Concludes Research Agreement with UK Venture for Identifying Target Molecules for New Cancer Drugs

Eisai announced on May 2 that its US research subsidiary H3 Biomedicine has entered into a joint research agreement with the UK venture company Horizon Discovery Ltd. for identifying and validating candidate molecule targets for novel anticancer agents. H3 Biomedicine,...read more